



TOR1-Q1: How does the seroprevalence in the adult and young wild boar sub-population evolve after the last detection PCR positive sample?

TOR1-Q2: How confident can we be that on-going surveillance activities would detect ASFV circulation?

TOR1-Q3: Are there any updates on uncertain attributes in ASF epidemiology that need to be taken into account?

TOR1-Q4: Which factors could lead to prolonged virus circulation (persistence)?

Data source = Surveillance data

Data source = Literature

Generalised estimation equations method

Sensitivity of on-going surveillance including hunted and found dead in EE assuming 1 % prevalence

**Section 4.1**  
Fast decline in seroprevalence of young animals, but up to 2 years in adult animals

**Section 4.2.**  
• Only in some regions in EE > 95% confidence to detect ASFV

Narrative literature review

**Section 4.3**  
• Mortality and case-fatality  
• Protective and maternal immunity  
• Transmission parameters

**Section 4.2**  
• Persistence in environment  
• Wild boar related factors  
• Virus related factors  
• Human-induced factors

**Considerable uncertainty remains on:**  
• Duration maternal/protective immunity  
• Mortality rate  
• Existence and role of carriers

**Decision: stochastic model needed to:**  
• Confirm population profiles  
• Test impact of different scenarios on duration virus circulation  
• Test alternative exit strategies

**Section 4.4.1: Confirm profiles in sub-populations for:**  
• Serology  
• Virus  
• Death due to ASF

**Section 4.4.2: Test impact of different scenarios on perpetuation ASFV circulation:**  
• Baseline scenario  
• Alternate duration maternal and protective immunity  
• Alternate case-fatality rate  
• Inclusion of carriers

**External scientific report: Test exit strategy- Iteration 1-2:**  
• Test existing tools (passive and active surveillance)  
• Inclusion of serology young WB without differentiation of different monitoring phases

**Lessons learnt:**  
• Serology in young WB only limited contribution  
• Need to differentiate strategy for large and small infected area  
• Need to split up screening and confirmation phase, especially in large areas

**Section 4.4.3.: Test exit strategy- Iteration 3:**  
• focus on passive surveillance split into screening and confirmation phases  
• intensification carcass search in confirmation phase

TOR2: Formulation of recommendations Exit Strategy **Section 5**